Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
9.23
+0.26 (2.94%)
Nov 21, 2024, 11:29 AM EST - Market open
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $3.70M in the quarter ending September 30, 2024, with 27.63% growth. This brings the company's revenue in the last twelve months to $24.49M, up 47.85% year-over-year. In the year 2023, Zevra Therapeutics had annual revenue of $27.46M with 170.26% growth.
Revenue (ttm)
$24.49M
Revenue Growth
+47.85%
P/S Ratio
15.59
Revenue / Employee
$354,913
Employees
69
Market Cap
492.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
Dec 31, 2019 | 12.84M | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Emergent BioSolutions | 1.13B |
Health Catalyst | 302.06M |
Treace Medical Concepts | 202.86M |
SIGA Technologies | 173.73M |
UroGen Pharma | 89.36M |
OmniAb | 20.41M |
Allogene Therapeutics | 43.00K |
ZVRA News
- 8 days ago - Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting - GlobeNewsWire
- 15 days ago - Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13 - GlobeNewsWire
- 21 days ago - Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - GlobeNewsWire
- 2 months ago - Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - GlobeNewsWire
- 2 months ago - Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C - GlobeNewsWire
- 2 months ago - US FDA approves Zevra's genetic disorder treatment - Reuters